Piper Sandler Maintains Neutral on TELA Bio, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 71.5%

Neg 71.5% Neu 0% Pos 0%

Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Neutral and lowers the price target from $1.25 to $1.